ライフサイエンスコーパス: SLCO1B1

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 evidence of a role for allelic variation in SLCO1B1.

2 n the organic anion transporter polypeptide, SLCO1B1.

3 pe alleles (n = 10), SLCO1B1*1b/*1b (n = 8), SLCO1B1*15/*15 (n = 7), SLCO1B1*5/*15 (n = 1), SLCO1B1*1

4 CO1B1*15/*15 (n = 7), SLCO1B1*5/*15 (n = 1), SLCO1B1*1a/*5 (n = 6), and SLCO1B3*4/*4 (n = 4) by using

5 explained by UGT1A1*93, ABCC1 IVS11 -48C>T, SLCO1B1*1b, ANC baseline levels, sex, and race (P < .000

6 s of SLCO1B1/1B3 wild-type alleles (n = 10), SLCO1B1*1b/*1b (n = 8), SLCO1B1*15/*15 (n = 7), SLCO1B1*

7 cid were evaluated in 36 healthy carriers of SLCO1B1/1B3 wild-type alleles (n = 10), SLCO1B1*1b/*1b (

8 pair statin metabolism; the reduced function SLCO1B1*5 allele impairs statin clearance and is associa

9 SLCO1B1*5 genotype and female sex were associated mild s

10 SLCO1B1*5 was associated with CAE (percent with > or = 1

11 he curve (AUC) is explained by ABCC2 -24C>T, SLCO1B1*5, HNF1A 79A>C, age, and CPT-11 dose (P < .0001)

12 O1B1*1b/*1b (n = 8), SLCO1B1*15/*15 (n = 7), SLCO1B1*5/*15 (n = 1), SLCO1B1*1a/*5 (n = 6), and SLCO1B

13 In candidate analysis, SNPs in SLCO1B1 and LDLR were confirmed as associated with LDL-C

14 nt of statin response, with the exception of SLCO1B1 and risk of myopathy.

15 equenced CYP2D6, CYP2C8, CYP2C9, CYP3A4, and SLCO1B1 and tested 7 reduced function alleles for associ

16 n a multivariate analysis including TPMT and SLCO1B1 as covariates, consistent with its influence on

17 on study of children with ALL, we identified SLCO1B1 as harboring multiple common polymorphisms assoc

18 yet heretofore low-priority candidate gene, SLCO1B1, as important determinants of methotrexate's pha

19 orvastatin concentration was associated with SLCO1B1 c.388A>G (P<0.01) and c.521T>C (P<0.05) and 4bet

20 x, ethnicity, dose, and time from last dose, SLCO1B1 c.521T>C (P<0.001) and ABCG2 c.421C>A (P<0.01) w

21 tested the hypothesis that rare variants in SLCO1B1 could affect methotrexate clearance and compared

22 From deep resequencing of SLCO1B1 exons in 699 children, we identified 93 SNPs, 15

23 The top variants in UGT1A1 and SLCO1B1 explain approximately 18.0 and approximately 1.0

24 lded a single nucleotide polymorphism in the SLCO1B1 gene for the organic anion-transporting polypept

25 However, knowledge of SLCO1B1 genotypes is believed to have clinical utility f

26 We verified lower function in vitro of four SLCO1B1 haplotypes that were associated with reduced met

27 ease processes, and the roles for UGT1A1 and SLCO1B1 in drug metabolism, these genetic findings have

28 nd identify two loci, SORT1/CELSR2/PSRC1 and SLCO1B1, not previously identified in GWAS.

29 phisms in the organic anion transporter gene SLCO1B1 (P = 2.1 x 10(-11)).

30 Two SNPs in SLCO1B1, rs11045879 (P = 1.7 x 10(-10)) and rs4149081 (P

31 e (AUC)0-48h increased by 26% (P < .001) per SLCO1B1 rs4149056 C allele.

32 The SLCO1B1 rs4149056 variant was significantly associated w

33 e 12p12.2 region was a non-synonymous SNP in SLCO1B1 (rs4149056, P = 6.7 x 10(-13)), which gives rise

34 re damaging NS variants constituted 17.8% of SLCO1B1's effects (1.9% of total variation) and had larg

35 earance: SLC10A1, SLC22A1, SLC22A7, SLC47A1, SLCO1B1, SLCO1B3, SLCO2B1, ABCB1, ABCB11, ABCC2, ABCC3,

36 e association of methotrexate clearance with SLCO1B1 SNP rs4149056.

37 ients (P = .018 and P = .017), as were other SLCO1B1 SNPs residing in different LD blocks.

38 ) = 1) and with a functional polymorphism in SLCO1B1, T521C (rs4149056; r(2) > 0.84).

39 enotypes for the top UGT1A1 variant, the top SLCO1B1 variant remained highly significant (P = 7.3 x 1

40 or other genetic and non-genetic covariates, SLCO1B1 variants accounted for 10.7% of the population v

41 SNPs in SLCO1B1 were also associated with GI toxicity (odds rati

42 gallstones, top bilirubin SNPs in UGT1A1 and SLCO1B1 were not associated.

43 icance of variants modulating toxicity (e.g. SLCO1B1 with simvastatin) has also been confirmed.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。